Preclinical News and Research

RSS

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

6 Mar 2015

Study shows how mutations that cause Alzheimer's disease lead to neurodegeneration, dementia

A study from researchers at Massachusetts General Hospital and Brigham and Women's Hospital reveals for the first time exactly how mutations associated with the most common form of inherited Alzheimer's disease produce the disorder's devastating effects.

5 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer.

4 Mar 2015

Apollo signs license option deal with Case Western to develop point-of-care blood analyzer

A blood test yields a wealth of information crucial to a person's health. What's needed is a device that is small and inexpensive, yet capable of quickly providing a thorough analysis using a very small sample.

4 Mar 2015

Common antidepressant medications not helpful for people with mood, anxiety disorders

Studies indicate that the majority of people with mood and anxiety disorders who receive the most commonly prescribed class of antidepressant medications, Selective Serotonin Reuptake Inhibitors or SSRI's, are not helped by these medications. SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood.

4 Mar 2015

Springer brings out new open access journal: International Journal of Implant Dentistry

Springer has launched a new open access journal, the International Journal of Implant Dentistry. Sponsored by the German Association of Dental Implantology and the Japanese Socieities of Oral Implantology, and published by SpringerOpen, the journal is dedicated to the exchange and discussion of new research in the field of implant dentistry.

4 Mar 2015

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

NI Research has released the March/April issue of NeuroPerspective, which features comprehensive reviews of two major areas: Schizophrenia and Spinal cord injury.

3 Mar 2015

Existing drug could help treat MS, other neurological diseases

Damage to myelin, the fatty insulator that enables communication between nerve cells, characterizes multiple sclerosis (MS) and other devastating neurological diseases.

3 Mar 2015

Data provides better understanding of genetic activity during lung cancer development

Scientists at the University of Granada, incollaboration with the universities of Harvard and Yale (United States) have provided new data for a better understanding of the alterations produced during the development of lung cancer, the tumour with the highest yearly death rate in Spain.

3 Mar 2015

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

1 Mar 2015

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed.

28 Feb 2015

Researchers reveal role of abdominal muscles in muscular dystrophy process

The muscular dystrophies are known to target various muscle groups differentially. In addition to making limb muscles weak, muscular dystrophy (MD) can also lead to decreased function of specific muscles involved in respiration causing breathing difficulties as well as leading to cardiac problems.

27 Feb 2015

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round.

27 Feb 2015

New cancer drug enters phase I clinical trials in humans

A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.

27 Feb 2015

Investigators caution parents, health care providers about use of general anesthetics in children

A group of anesthesiologists and toxicologists today issued a caution to parents and health care professionals about the use of general anesthetics in children.

27 Feb 2015

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine, has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a child's life by age 10.

26 Feb 2015

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis.

26 Feb 2015

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

An international team of scientists including CureLab Oncology, Inc. (Boston), University of Camerino (Italy), and Boston University have serendipitously discovered a DNA vaccine, which systemically alleviates chronic inflammation in the body. Since osteoporosis is an inflammatory disease, preventive and therapeutic effects of the new vaccine were demonstrated on mouse models with osteoporosis.

26 Feb 2015

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital.

26 Feb 2015

Preclinical News and Research

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Study shows how mutations that cause Alzheimer's disease lead to neurodegeneration, dementia

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Novogen's TRXE-009 therapy shows promise against brain cancer

Apollo signs license option deal with Case Western to develop point-of-care blood analyzer

Common antidepressant medications not helpful for people with mood, anxiety disorders

Springer brings out new open access journal: International Journal of Implant Dentistry

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

Existing drug could help treat MS, other neurological diseases

Data provides better understanding of genetic activity during lung cancer development

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Researchers reveal role of abdominal muscles in muscular dystrophy process

Chiasma closes $70 million Series E financing round

New cancer drug enters phase I clinical trials in humans

Investigators caution parents, health care providers about use of general anesthetics in children

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics